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SCF and c-kit in Mastocytosis – a Pandora’s Box Holding More
Theories Than Proven Facts
To the Editor:
In their recently published study in this journal, Longley et al
(1997) have tried to further elucidate the possible pathomechanisms
of mastocytosis, showing that a mutated c-kit, the receptor of the
mast cell and stem cell growth factor (SCF), as described in several
patients with this disease (Nagata et al, 1995; Longley et al, 1996),
fails to explain the phenotype of mast cells in diverse organs of
these patients. This is in line with recent findings and ongoing
work in our laboratory showing that skin fibroblasts and keratinocytes
secrete mast cell growth factors other than SCF. Even mast cells
bearing the c-kit mutation, like the human leukemic mast cells
HMC-1, respond to these factors with increased differentiation
(Welker et al, 1995; Czarnetzki et al, 1996).1
Furthermore, as recently reported by us,2 six children with
mastocytosis failed to exhibit a c-kit mutation in lesional skin mast
cells. This defect has been described by Longley et al (1996) in
skin mast cells of an adult with progressive disease and was also
found by us in patients with benign adult-onset disease (N 5 6).2
The findings thus underline the well-known fact that mastocytosis
is heterogeneous with regard to not only its organ manifestations,
but also its clinical manifestations and its prognosis.
The reasons for the mostly focal increase of mast cell accumulation
in children are as yet unclear. Similarly, as noted by Longley et al
(1997), the c-kit mutation in adults is far from explaining the cause
and the diverse clinical aspects of the disease. Interestingly, an
observation that might be linked to or caused by the same
mechanism responsible for the c-kit mutation relates to the recently
described increase in chromosomal aberrations in the bone marrow
of adults with mastocytosis (Lishner et al, 1996). This fits in turn
with the low, but clearly increased risk of malignant disease in
adult-onset mastocytosis (Czarnetzki, 1986).
As a final point, the proposal that SCF might not be properly
metabolized in the skin of mastocytosis patients (Longley et al,
1993), as nicely outlined again in a recent editorial by Tharp (1997),
should be commented on. In this thorough review of the subject,
Tharp apparently missed a publication by our group, showing that
this theory is unlikely to hold for most mastocytosis patients
(Hamann et al, 1995). In skin biopsies of 11 adults and two children
with cutaneous and also partly systemic disease, we could not detect
the increased intercellular SCF deposits described by Longley et al
(1993) in their one patient, although we studied several antibodies
to rule out technical problems as an explanation for the divergent
findings. Our data fit on the other hand with the normal SCF
mRNA levels in the skin of the patient described by Longley et al
(1993), suggesting that SCF synthesis is normal in the lesional skin
of these patients.
The many open questions discussed so far make it apparent that
much needs to be done to further elucidate the cause and
pathogenesis of different types of mastocytosis as well as the role
played by SCF or other mast cell growth factors in this process.
Nevertheless, opening of the Pandora’s box with the discovery of
SCF and the mutation of its c-kit receptor in a number of patients
with the disease has stimulated new interest in this problem and
has already yielded an interesting body of new data. These and
1Welker P, Grabbe J, Gru¨tzkau A, Henz BM: Influence of the growth factors
NGF and GM-CSF on the expression of mast cell characteristics. J Allergy Clin
Immunol 97:266, 1996 (abstr.)
2Bu¨ttner C, Heide I, Sepp N, Henz BM: Identification of a c-kit mutation
in adult- but not in childhood onset mastocytosis. Arch Derm Res
289:A39, 1997 (abstr.).
future studies will hopefully provide further insights into not only
the pathogenesis, but also the more effective treatment of the disease.
Beate M. Henz
Department of Dermatology
Free University of Berlin, Rudolf Virchow Hospital
Berlin, Germany
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Reply:
We thank Professor Henz and her group for their interest in our paper.
As they have shown in their work and writings, it is indeed clear that
diverse factors must affect mast cell growth and differentiation. With
regard to stem cell factor (SCF) metabolism in the skin of patients
with mastocytosis, I believe that some of this group’s findings confirm
some of our work but that technical factors may have contributed to
their inability to find soluble SCF in mastocytosis lesions (Hamann
et al, 1995).
By way of background, SCF, which is also known as mast cell
growth factor, affects the growth and function of both mast cells and
melanocytes. Although SCF is a relatively strong melanocyte mitogen,
it is even more effective at inducing melanocyte pigment production
(Halaban et al, 1993). SCF is normally produced as a transmembrane
molecule, but the extracellular portion may be released as a soluble
molecule by cleavage of mature SCF in the extracellular juxta-
membrane region. When we first discovered that keratinocytes produce
SCF, we were able to demonstrate it only as a cell associated molecule
in normal skin (Longley et al, 1993). In mastocytosis, however, we
found a qualitative change in the distribution of epidermal SCF,
immunoreactive SCF was present mainly ‘‘between’’ the keratinocytes
and there was decreased staining of keratinocytes, suggesting a switch
from a predominantly membrane bound form to a soluble form of the
molecule. I emphasize that we reported staining of keratinocyte-
associated SCF was decreased in lesional skin. We have not been able
to identify changes in SCF mRNA (Longley et al, 1993) or changes
in the absolute amounts of SCF present (our unpublished data), so we
currently believe that there is increased cleavage of SCF with excessive
release of a soluble form from the normally membrane bound form.
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It should be noted that whereas both the membrane bound form and
the soluble form of SCF can stimulate the SCF receptor, there are
differences in the duration and perhaps signaling pathways stimulated
by these different forms of the molecule (Toksoz et al, 1992; Miyazawa
and Williams, 1995; Wehrle-Haller and Weston, 1995)
Soluble cutaneous SCF appears to be present at low levels, and we
have only been able to demonstrate it in skin by using a sensitive
immunoperoxidase technique with long incubations (Longley et al,
1993, 1996, 1997a). Our original studies used formalin fixed tissue, in
which there may be extensive cross-linking of proteins. This could
prevent loss of a small soluble molecule such as SCF. Our collaborators
have reproduced our results in another laboratory using frozen sections,
and the same immunoperoxidase detection system (Weiss et al, 1995),
but with a different, commercially available antibody. Professor Henz’s
group used frozen samples with an alkaline phosphatase-anti-alkaline
phosphatase technique, different antibodies, and shorter incubations. I
believe the difference in the detection systems is most important
although it is possible that there also may have been loss of some
soluble SCF from the frozen sections or differences in the antibody
recognition. Despite those differences, Professor Henz’s group did
confirm our result of decreased keratinocyte SCF staining in lesions of
urticaria pigmentosa.
The issue of the presence or absence of soluble SCF and whether
or not keratinocyte associated as SCF remains the same or is decreased
in mastocytosis lesions is not trivial if we are to understand the
pathogenesis of this disease and the potential functions of mast cells in
the skin. We have clearly demonstrated that at least some forms of
urticaria pigmentosa are true neoplasms characterized by activating
cKIT somatic mutations limited to mast cells (Longley et al, 1996).
The c-KIT activating mutations we found in mast cells could not
directly affect melanocytes, and therefore cannot be invoked as an
explanation for increased melanin production seen both clinically and
histopathologically in lesions of cutaneous mastocytosis. What is a
possible explanation for all three observations, the hyperpigmentation,
the altered distribution of SCF, and the presence of activating SCF
mutations? We have hypothesized that neoplastic mast cells, whose
proliferation is driven by mutated mast cell growth factor receptor
(KIT), induce the release of membrane bound keratinocyte SCF
(Longley et al, 1993). The resulting solublized SCF might then stimulate
melanocytes in the lesions to produce melanin, and also stimulate the
mast cells to further proliferation. In support of this theory, we have
recently discovered that the mast cell enzyme chymase, which can be
present in extremely high concentrations in the vicinity of mast cells,
is capable of specifically cleaving SCF, leaving a soluble, bioactive
fragment (Longley et al, 1997b). We currently favor the hypothesis
The DNA Repair Capacity of Melanoma Cells
To the Editor:
I read with interest the article by Wei et al (1997) regarding the
correlation between DNA repair capacity and metastatic potential of
K-1735 murine melanoma cells; however, the concept of failure of
apoptosis in cancer has not been adequately considered.
The development of cancer is related to the survival of abnormal
cells within preneoplastic lesions by a failure of apoptosis due to the
dysfunction of tumor suppressor genes such as p53 or the existence of
other genes that promote cell survival such as bcl-2. Furthermore,
progression of neoplasia to metastasis may be associated with an
increased rate of mutations and greater resistance to apoptosis. The
percentage of p53 mutations is higher in metastatic melanoma lesions
than in primary tumors (Sparrow et al, 1995) and highly metastatic
B16 melanoma cells exhibit superior survival and resistance to apoptosis
compared with poorly metastatic cells (Glinsky and Glinsky, 1996).
that the neoplastic mast cells in mastocytosis release chymase, which
causes increased conversion of membrane bound keratinocyte SCF to
soluble SCF, which then feeds back to stimulate both mast cell growth
and melanocyte pigment production. This phenomenon would explain
the appearance of soluble SCF and the decrease in keratinocyte
associated SCF. This represents a novel feedback loop, in which a cell
releases a substance which causes secondary release from the surrounding
environment of a growth factor that is necessary for proliferation of
the cell, and has features of both paracrine and autocrine stimulation.
We have therefore named it ‘‘parautocrine’’ stimulation. We believe
that parautocrine stimulation in mastocytosis represents an exaggeration
of a process that is normally seen in inflammatory conditions involving
mast cells in the skin, and could be responsible for such phenomenon
as post-inflammatory hyperpigmentation and the proliferation of mast
cells at sites of chronic inflammation.
B. Jack Longley
Section of Dermatopathology
College of Physicians and Surgeons
Columbia University
New York
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In the host cell reactivation assay used by Wei et al (1997), damaged
plasmid (pCMVcat) encoding chloramphenicol acetyl transferase (CAT)
is transfected into cells. Following incubation, CAT activity is taken
to represent the extent of repair of pCMVcat by the various cell lines
and thus their DNA repair capacity. There is no mention of the
number of cells surviving per well at the end of the incubation.
An alternative interpretation of their results is that repair-proficient
skin fibroblasts, nonmetastatic, and metastatic melanoma cell clones
have similar DNA repair capacity; however, although nonmetastatic
melanoma cells and repair-proficient skin fibroblasts have functioning
p53 pathways, the metastatic cell clones have abnormal apoptotic
pathways. This results in a greater CAT acitivity per extract in the
assay, not due to a greater DNA repair capacity, but to greater survival
of the metastatic melanoma cells from a failure of apoptosis to occur
following transfection of damaged DNA (pCMVcat).
